Actinogen Medical

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Actinogen Medical (ASX:ACW): an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with significant neurological and metabolic diseases, including Alzheimer’s disease (AD).

Actinogen Medical’s lead drug, Xanamem, has been specifically designed to reduce production of excess cortisol in the brain via antagonism of neuronally expressed 11β-HSD1. Chronically raised cortisol is a key risk factor for AD, and the association between raised cortisol and cognitive decline has been well documented in the scientific literature. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with AD and a range of other neurological disorders.

Actinogen is refining a clinical development strategy aimed at initiating multiple phase II studies; including in AD (patients with mild cognitive impairment), cognitive impairment in schizophrenia, diabetes, and other indications.
Ticker:
ACW
Exchange:
Australian Stock Exchange (ASX)
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Xanamem
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Family of brain-penetrant 11B-HSD1 inhibitors with Xanamem as lead compound
Speaker
photo
CEO & Managing Director
Actinogen Medical